Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN III 20 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN III 20 versus LIQREV.
LIPOSYN III 20% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn III 20% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories. It serves as a source of energy and prevents essential fatty acid deficiency by supplying triglycerides that are hydrolyzed to free fatty acids and glycerol for metabolism.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Adults: 500 mL to 2500 mL per day via continuous intravenous infusion (including peripheral or central vein); typical rate: 0.5-1 mL/kg/h initially, increasing to 1.5-2 mL/kg/h as tolerated. Maximum infusion rate: 2.5 mL/kg/h.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
The terminal elimination half-life of infused triglycerides is approximately 0.5–1 h (33–60 min). Clearance is saturable; at high infusion rates, half-life may prolong.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Primarily eliminated via endogenous lipid metabolic pathways (beta-oxidation in tissues). <5% excreted unchanged in urine; minimal biliary/fecal elimination.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion